Global Apixaban Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

PUBLISHED: September 1, 2024

PAGES: 129 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The global demand for Apixaban Market is presumed to reach the market size of nearly USD 33.71 Billion by 2032 from USD 17.36 Billion in 2023 with a CAGR of 7.65% under the study period 2024-2032.

Apixaban is an anticoagulant drug used to treat and prevent blood clots and strokes in people with nonvalvular atrial fibrillation. Apixaban is a blood thinner that is intended to prevent blood clots from forming following hip or knee replacement surgery, which can lead to lungs blood clots (pulmonary embolism). It's used instead of warfarin because it doesn't require blood tests or dietary restrictions. Apixaban belongs to the factor Xa inhibitors class of drugs. It works by stopping a natural substance that assist in the formation of blood clots. Apixaban is marketed under the name Eliquis. It is taken orally in the form of tablets. The most common side effects are bleeding and nausea. It is not recommended to take apixaban while pregnant or breastfeeding. In people with mild renal issues, it appears to be relatively safe to use. Eliquis interacts with fewer medications than warfarin.

MARKET DYNAMICS

Rising therapeutic indications for apixaban, an increase in the prevalence of atrial fibrillation, venous thromboembolism, and stroke are substantially contributing to the market growth. Furthermore, an increase in the geriatric population, an increase in the prevalence of obesity are supplementing market development. Additionally, a rising surge in healthcare expenditures worldwide and increasing government and private organizations investing significantly in healthcare research and development are other key factors driving the apixaban market. Moreover, rising potential in emerging economies, and increasing technological advancements and modernization in the healthcare sector, will expand the market for apixaban. However, apixaban's side effects, such as an increased risk of thrombotic events and bleeding if taken too soon, are likely to limit its use, thereby hampering the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Apixaban. The growth and trends of Apixaban industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Apixaban market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dosage Form

Capsule
Tablet

By End-User

Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Apixaban market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Apixaban market include F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Eisai Co. Ltd, Sanofi S.A., Yino Pharma Limited, Mylan N.V., Bristol Myers Squibb Company, Abbott Laboratories, Hebei Changshan Biochemical Pharmaceutical Co. Ltd, Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd., Aspen Holdings, Fresenius Kabi AG, Pfizer Inc., Others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11216577

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. APIXABAN - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Dosage Form
- 3.7.2 Market Attractiveness Analysis By End-User
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL APIXABAN MARKET ANALYSIS BY DOSAGE FORM

5.1. Overview By Dosage Form
5.2. Historical and Forecast Data
5.3. Analysis By Dosage Form
5.4. Capsule Historic and Forecast Sales By Regions
5.5. Tablet Historic and Forecast Sales By Regions

6. GLOBAL APIXABAN MARKET ANALYSIS BY END-USER

6.1. Overview By End-User
6.2. Historical and Forecast Data
6.3. Analysis By End-User
6.4. Hospitals Historic and Forecast Sales By Regions
6.5. Clinics Historic and Forecast Sales By Regions
6.6. Retail Pharmacies Historic and Forecast Sales By Regions
6.7. Online Pharmacies Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL APIXABAN MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE APIXABAN COMPANIES

8.1. Apixaban Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF APIXABAN INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. F. Hoffmann-La Roche Ltd
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Hikma Pharmaceuticals PLC
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Eisai Co. Ltd
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Sanofi S.A.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Yino Pharma Limited
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Mylan N.V.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Bristol Myers Squibb Company
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Abbott Laboratories
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Hebei Changshan Biochemical Pharmaceutical Co. Ltd
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Nanjing Jianyou Biochemical Pharmaceutical Co. Ltd.
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments
9.13. Aspen Holdings
- 9.13.1 Company Overview
- 9.13.2 Company Revenue
- 9.13.3 Products
- 9.13.4 Recent Developments
9.14. Fresenius Kabi AG
- 9.14.1 Company Overview
- 9.14.2 Company Revenue
- 9.14.3 Products
- 9.14.4 Recent Developments
9.15. Pfizer Inc.
- 9.15.1 Company Overview
- 9.15.2 Company Revenue
- 9.15.3 Products
- 9.15.4 Recent Developments
9.16. Others
- 9.16.1 Company Overview
- 9.16.2 Company Revenue
- 9.16.3 Products
- 9.16.4 Recent Developments